Publications by authors named "Guohe Lin"
The Effects of Polystyrene Microplastics and Copper Ion Co-Contamination on the Growth of Rice Seedlings.
Nanomaterials (Basel)
December 2024
Microplastics (MPs) are emerging pollutants of global concern, while heavy metals such as copper ions (Cu) are longstanding environmental contaminants with well-documented toxicity. This study investigates the independent and combined effects of polystyrene microplastics (PS-MPs) and Cu on the physiological and biochemical responses of rice seedlings ( L.), a key staple crop.
View Article and Find Full Text PDFBackground: The addition of durvalumab or pembrolizumab to gemcitabine and cisplatin (GP) has been approved to statistically improve survival outcomes in patients with advanced biliary tract cancer. However, since the survival time was only prolonged by about two months, doubts have been raised. In this analysis, we aimed to evaluate the efficacy of combining durvalumab or pembrolizumab with GP chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- * Using data from six clinical trials with 140 ATC patients, the research found that patients had a median overall survival of 4.8 months and progression-free survival of 2.6 months when treated with TKIs, with response rates deemed low (9% objective response rate).
- * The findings indicate that while TKIs showed some potential, they provided limited benefits, suggesting future research should explore combination therapies with chemotherapy, radiotherapy, or immunotherapy to improve treatment outcomes.
Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies.
Front Endocrinol (Lausanne)
July 2024
Article Synopsis
- Anaplastic thyroid cancer (ATC) typically lacks effective mutational driver genes, making chemotherapy the main treatment option, despite its limited benefits; this study focuses on analyzing data from prospective clinical trials since 2010.* -
- Researchers reviewed six trials involving 232 patients, finding median overall survival at 6.0 months and progression-free survival at 3.2 months, with objective response rates of 21% and disease control rates of 64%.* -
- While chemotherapy-based approaches showed some effectiveness against ATC, they did not significantly extend patient survival, highlighting the need for more effective and safer treatment options.*
Background: Tyrosine kinase inhibitors (TKIs) contribute to the treatment of patients with anaplastic thyroid cancer (ATC). Although prospective clinical studies of TKIs exhibit limited efficacy, whether ATC patients benefit from TKI treatment in real-world clinical practice may enlighten future explorations. Therefore, we conducted this effective analysis based on real-world retrospective studies to illustrate the efficacy of TKI treatment in ATC patients.
View Article and Find Full Text PDFBackground: Immunotherapy has revolutionized the treatment of hepatocellular carcinoma (HCC). However, whether adding immunotherapy to antiangiogenic therapy benefits patients with unresectable HCC (uHCC) more in the first-line setting remains controversial.
Objective: In this analysis, we compared the clinical outcomes of lenvatinib monotherapy with atezolizumab plus bevacizumab combination therapy in advanced uHCC in real-world clinical practice.
Background: Novel-fosfamides (NFOs) belong to active metabolites of ifosfamide that bypass the generation of toxic byproducts. In this analysis, we aimed to comprehensively assess the benefits and risks of NFO monotherapy or in combination with doxorubicin (DOX) versus single-drug DOX in previously untreated patients with advanced soft-tissue sarcoma (ASTS).
Methods: Online PubMed, Web of Science, Embase, and Cochrane CENTRAL databases were systematically searched on April 26, 2022.
Background: Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets the human trophoblast cell-surface antigen 2 to deliver SN-38 to cancer cells. In this study, we assessed the efficacy and safety of SG in patients with relapsed or refractory metastatic triple-negative breast cancer (RM-TNBC).
Methods: For this integrated analysis, from inception to January 2, 2023, we searched PubMed, Web of Science, Embase, and Cochrane library databases for prospective studies that evaluated SC in RM-TNBC patients.
Background: Adebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, whether adebrelimab is superior to durvalumab and atezolizumab remains unclear. Therefore, we, in this study, aimed to compare the survival data of adebrelimab (CAPSTONE-1 trial) with durvalumab (CASPIAN trial) and atezolizumab (IMpower133 trial) in the first-line setting of ES-SCLC patients.
View Article and Find Full Text PDFArticle Synopsis
- Taxane chemotherapy is the standard treatment for advanced non-small cell lung cancer (NSCLC), but there's ongoing debate on the effectiveness of combining immunotherapy with chemotherapy compared to using either alone.
- The study analyzed data from eight trials involving 4,398 patients to compare overall survival (OS) and progression-free survival (PFS) between various treatments, focusing on immunotherapy options like pembrolizumab.
- Results showed that pembrolizumab 10 mg/kg had the best OS outcomes, while the combination of pembrolizumab 200 mg with docetaxel had the best PFS, suggesting these treatments could be more beneficial for NSCLC patients who haven't received immunotherapy yet.
Background: Non-small-cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutant occurs in 3% of NSCLCs. Targeted agents for this population remain an unmet need. In this analysis, we pooled-analyzed the efficacy and safety of poziotinib, a novel tyrosine kinase inhibitor, in HER2 exon 20 mutant NSCLC.
View Article and Find Full Text PDFBackground: Immunotherapy has revolutionized the treatment of advanced lung cancer. Nevertheless, it remains unclear whether adding stereotactic body radiotherapy (SBRT) to immunotherapy (IT) further improves responses and survival outcomes. Therefore, in this pooled analysis, we comprehensively compared IT plus SBRT with IT alone in patients with advanced lung cancer.
View Article and Find Full Text PDFBackground: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy is the standard of care in treating advanced non-small cell lung cancer (NSCLC). Nevertheless, whether adding pemetrexed-based chemotherapy to EGFR-TKI targeted therapy furtherly prolongs survival outcomes and improves responses remains controversial. Therefore, we conducted this pooled analysis to compare the efficacy and tolerability between gefitinib plus pemetrexed-based chemotherapy and gefitinib alone in the first-line treatment of advanced NSCLC patients with mutated EGFR.
View Article and Find Full Text PDFArticle Synopsis
- UHRF1 is identified as an oncogene in thyroid cancer, with a specific focus on its role in promoting metastasis, which the study aims to investigate.
- Experiments revealed that overexpressing UHRF1 enhances the metastatic ability of papillary thyroid cancer cells, while reducing its levels decreases metastasis in anaplastic thyroid cancer cells.
- The study suggests that UHRF1 promotes metastasis through a pathway where it activates the transcription factor c-Jun/AP-1, leading to increased expression of IL-6 and MIF, indicating a potential new target for therapeutic intervention in thyroid cancer patients.
Background: Adding induction chemotherapy to concurrent platinum-based chemoradiotherapy has significantly prolonged the survival time of patients with locoregionally advanced nasopharyngeal carcinoma. In this study, we intend to evaluate the survival outcomes, responses, and incidences of toxicities of induction chemotherapy and the differences between different strategies.
Methods: A comprehensive search was conducted in PubMed, Embase, Web of Science, and Cochrane CENTRAL on August 10, 2021.
Article Synopsis
- - Cemiplimab is recommended for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), and a comparative analysis was conducted to assess its efficacy and safety across various studies.
- - The analysis included 398 patients from three retrospective studies and 219 patients from three prospective studies, revealing objective response rates (ORRs) of 53% for retrospective studies and 45% for prospective studies.
- - Although cemiplimab shows promise for treating CSCC, the study found higher incidences of treatment-related adverse events (TRAEs) in prospective studies, particularly fatigue, diarrhea, and pruritus, emphasizing the need for monitoring toxicities during treatment.
Background: The prognosis of patients with relapsed Ewing sarcoma is poor. In this study, we aimed to pooled-analyze the efficacy and safety of the combination of irinotecan and temozolomide in treating patients with relapsed Ewing sarcoma.
Methods: PubMed, Cochrane CENTRAL, Web of Science, and EMBASE were systematically searched on September 27, 2021.
Article Synopsis
- The study aimed to find the best treatment strategy for locoregionally advanced nasopharyngeal carcinoma (LANPC) using Bayesian network analysis.
- Data was gathered from randomized clinical trials comparing three treatment approaches: induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT), concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT+AC), and concurrent chemoradiotherapy alone (CCRT).
- The findings revealed that IC+CCRT outperformed CCRT significantly for various 5-year outcomes, suggesting it as the preferred treatment option, while CCRT+AC didn't significantly enhance survival compared to the other methods despite high survival rates.
Background: Doxorubicin/Adriamycin (ADM) alone or combined with ifosfamide (IFO) (AI) is available for previously untreated advanced soft tissue sarcoma (ASTS). However, the clinical choice between them remains controversial. In this pooled analysis, we comprehensively compared the efficacy and tolerability of AI versus ADM in patients with ASTS.
View Article and Find Full Text PDFArticle Synopsis
- Olanzapine, an antipsychotic, is being used as part of antiemetic treatment for breast cancer patients experiencing nausea and vomiting from certain chemotherapy regimens.
- A review of multiple studies found that patients receiving olanzapine showed significantly higher rates of complete response (no vomiting and no rescue medication) and no nausea compared to those receiving a placebo.
- The findings suggest that olanzapine is an effective and cost-efficient option for managing chemotherapy-induced nausea and vomiting in breast cancer patients.
Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been demonstrated to improve the anti-cancer effects in combination with radiotherapy. However, the tolerability and safety of adding GM-CSF to radiotherapy in thoracic cancer patients need to be further explored.
Methods: Between June 2020 and Sep 2020, seven patients with thoracic cancer were treated with concurrent radiotherapy and GM-CSF (200 µg subcutaneously injected q.
[This corrects the article DOI: 10.1155/2020/2368164.].
View Article and Find Full Text PDFArticle Synopsis
- Adjuvant trastuzumab is a key treatment for early breast cancer patients with a positive HER2 receptor, with the standard duration being 12 months, although the effectiveness of a 6-month duration remains debated.
- A meta-analysis of three clinical studies involving nearly 8,000 patients was conducted to compare disease-free survival (DFS) and overall survival (OS) between 6-month and 12-month treatments, with specific non-inferiority thresholds.
- The results indicated that while 6 months of treatment did not meet non-inferiority for DFS, it was found to be non-inferior for OS; however, the study concluded that 12 months should continue to be the standard due to potential disease progression concerns
Purpose: Effective treatment options for intrahepatic cholangiocarcinoma (ICC) are limited. This study was intended to explore the efficacy and safety of apatinib in advanced ICC with lymph node metastasis or distant metastasis.
Patients And Methods: The efficacy and toxicity of apatinib were evaluated in patients with ICC between November 2017 and March 2020 at the Second Affiliated Hospital of Anhui Medical University.
Background: The prognosis of patients with extensive-stage small cell lung cancer (SCLC) is poor. Adding an immune checkpoint inhibitor (ICI) to chemotherapy may exert a synergistic effect and improve survival outcomes. However, for treatment-naive extensive-stage SCLC patients, the efficacy of immunotherapy in combination with cytotoxic chemotherapy remains controversial.
View Article and Find Full Text PDF